Actively Recruiting
Evaluating Albumin-Bound Paclitaxel With Antiangiogenic Agents for First-Line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer
Led by The First Affiliated Hospital of Bengbu Medical University · Updated on 2026-09-04
128
Participants Needed
1
Research Sites
11 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for relapsed or metastatic triple-negative breast cancer TNBC, a form of breast cancer that does not respond to hormone or HER-2 targeted therapies. This study is a phase 2, randomized, open-label trial enrolling 128 female patients who have not received systematic treatment for their advanced TNBC. The goal is to assess the safety and effectiveness of albumin-bound paclitaxel alone or combined with antiangiogenic agents in this patient group. Participants are randomly assigned to one of three groups albumin-bound paclitaxel alone given by intravenous infusion every 3 weeks albumin-bound paclitaxel plus daily oral apatinib mesylate tablets every 3 weeks or albumin-bound paclitaxel plus intravenous bevacizumab every 3 weeks. Drug doses may be adjusted based on side effects, with specific minimum doses allowed. Patients continue treatment until disease progression, intolerable toxicity, death, or withdrawal by patient or investigator. During the study, participants will undergo regular assessments including imaging to measure tumor response and blood tests to monitor biomarkers like VEGF-A expression. The main outcome measured is progression-free survival over 2 years. Secondary outcomes include overall survival, response rates, clinical benefit rate, and recording of adverse events. Safety data and potential predictive biomarkers will also be analyzed. The study is expected to complete by December 2027.
CONDITIONS
Brief Title
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Research Team
J
Jing Liu, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here